Eugia Pharma Specialities Limited

Eugia Pharma Specialities Limited, incorporated on April 17, 2013, is a public limited company based in Hyderabad, Telangana, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24297TG2013PLC087048.

As of March 31, 2025, Eugia Pharma reported an authorized capital of ₹800 crore and a paid-up capital of ₹621.01 crore. The company's registered office is located at Plot No.2, Maitrivihar, Ameerpet, Hyderabad, Telangana 500038, India.

Eugia Pharma operates multiple manufacturing facilities in India, specializing in the production of finished pharmaceutical formulations. These facilities are equipped to handle a diverse range of dosage forms, including tablets, capsules, syrups, and injections. The company's manufacturing plants are strategically located to cater to both domestic and international markets.

The leadership team at Eugia Pharma includes:

• Yugandhar Puvvala: Chief Executive Officer (CEO) and Executive Director, appointed on December 27, 2021.

• Madan Mohan Reddy Mettu: Director, serving since April 17, 2013.

• Veerayya Chowdary Kosaraju: Director, appointed on December 1, 2021.

• Santhanam Subramanian: Director, appointed on October 1, 2021.

• Ragunathan Kannan: Director, appointed on December 1, 2021.

• Sundari Raviprasad Pisupati: Director, appointed on December 1, 2021.

Eugia Pharma has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for various products, enabling it to supply finished pharmaceutical formulations to these regions. Eugia Pharma's commitment to quality and compliance with international standards has facilitated its market access in these territories.

Eugia Pharma has expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), enhancing their acceptance and availability in these regions. This prequalification underscores Eugia Pharma's dedication to meeting global health standards and addressing the pharmaceutical needs of diverse populations.

Eugia Pharma's geographic strategy involves diversification across multiple regions, including both regulated and emerging markets. This approach mitigates concentration risk and positions the company to leverage growth opportunities worldwide. The strategic direction focuses on expanding market reach while maintaining a strong presence in key therapeutic areas.

Eugia Pharma's manufacturing facility, Unit III, located in Hyderabad, Telangana, was inspected by the U.S. Food and Drug Administration (FDA) from January 22 to February 2, 2024. The inspection identified significant violations of Current Good Manufacturing Practice (CGMP) regulations, leading to a warning letter issued on August 15, 2024. The company has acknowledged the observations and is taking corrective actions to address the issues raised.

Eugia Pharma's manufacturing facilities have been prequalified by the World Health Organization (WHO), ensuring that its products meet international quality standards. Additionally, the company holds European Union Good Manufacturing Practice (EU GMP) certificates, affirming its compliance with EU regulations for pharmaceutical manufacturing. These certifications facilitate the company's access to global markets and reflect its commitment to quality assurance.

Eugia Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has obtained approvals from state drug controllers and possesses export No Objection Certificates (NOCs), enabling it to export pharmaceutical products to various international markets. These regulatory approvals demonstrate Eugia Pharma's adherence to national standards and its capability to meet global pharmaceutical requirements.

On August 15, 2024, the FDA issued a warning letter to Eugia Pharma's Unit III facility, citing significant violations of CGMP regulations identified during an inspection conducted from January 22 to February 2, 2024. The company has acknowledged the observations and is implementing corrective actions to address the issues raised.

Eugia Pharma operates in a competitive landscape with several key players in the pharmaceutical industry. The company's focus on finished pharmaceutical formulations, including advanced antibiotics and oncology products, positions it in direct competition with other manufacturers specializing in these therapeutic areas. Market share dynamics and competitive strategies are continually evolving, requiring Eugia Pharma to adapt and innovate to maintain its market position.

Eugia Pharma's key differentiators include its comprehensive portfolio of finished pharmaceutical formulations, with a strong emphasis on advanced antibiotics and oncology products. The company's commitment to quality, as evidenced by WHO prequalification and EU GMP certifications, enhances its reputation in the global market. Additionally, Eugia Pharma's strategic geographic diversification and focus on emerging markets provide a competitive edge in addressing diverse healthcare needs.

Eugia Pharma's current strategic direction centers on expanding its presence in both regulated and emerging markets, with a particular focus on advanced antibiotics and oncology products. The company is investing in research and development to enhance its product portfolio and address unmet medical needs. Future outlooks indicate a continued emphasis on innovation, quality assurance, and market diversification to sustain growth and competitiveness.

Eugia Pharma has demonstrated a strong track record in pharmaceutical manufacturing, with a significant export volume of $170.1 million USD across 3,898 shipments. The company's portfolio includes 49 products across 14 therapeutic categories, indicating a diverse and consistent supply capability. Reliability indicators such as regulatory approvals, including WHO prequalification and EU GMP certifications, further attest to Eugia Pharma's commitment to quality and dependability.

Importers should verify the following certifications when considering Eugia Pharma as a supplier:

• FDA Facility Registration: Confirm the facility's registration status with the U.S. FDA to ensure compliance with U.S. regulations.

• WHO-GMP Certification: Verify the WHO Good Manufacturing Practice certification to ensure adherence to international quality standards.

• EU GMP Certification: Check the EU Good Manufacturing Practice certification to confirm compliance with European Union regulations.

• ISO Certifications: Review any ISO certifications related to quality management systems to assess the company's commitment to quality assurance.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Eugia Pharma directly.

When conducting due diligence on Eugia Pharma, consider the following steps:

• Regulatory Compliance: Verify the company's compliance with relevant regulatory bodies, including the FDA, WHO, EU, and CDSCO.

• Quality Certifications: Confirm the validity of quality certifications such as WHO-GMP, EU GMP, and ISO.

• Financial Health: Review the company's financial statements to assess profitability, revenue growth, and financial stability.

• Supply Chain Reliability: Evaluate the consistency and reliability of the company's supply chain, including lead times and delivery performance.

• Reputation and References: Seek references from existing clients and partners to gauge the company's reputation and reliability.

Red flags to watch for include unresolved regulatory issues, lack of up-to-date certifications, financial instability, and